Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
12/6 17:05
Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market sh...